AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD

Current share price for 1AD : $0.004 -0.001 (-20%)⁺

Announcement

$2.5m placement

Release

4 May 2026 9:47AM

Price at Release

$0.005

Full Release

Summary

AdAlta Limited (ASX:1AD) has successfully raised A$2.5 million through a private placement at A$0.004 per share to sophisticated investors, facilitated by 62 Capital Pty Ltd. The raised funds will be employed to advance the development of BZDS1901, a next-generation CAR-T cell therapy for treating advanced mesothelioma, and to execute AdAlta's 'East to West' strategy, which brings together Asian innovation with Western regulatory practices. The placement includes attaching options and requires shareholder approval for a portion of the issuance. The financing supports the relocation of manufacturing to Australia, enhancing the reliability and scalability of CAR-T products.

Key Points

AdAlta Limited has raised A$2.5 million through a private placement.
The placement was to sophisticated investors at A$0.004 per share, which is a discount to the closing price and VWAP.
The proceeds will help advance the development of BZDS1901, a CAR-T cell therapy for advanced mesothelioma.
AdAlta is implementing an 'East to West' strategy, integrating Asian innovation with Western regulatory and manufacturing standards.
AdAlta's CAR-T therapy BZDS1901 has shown promising clinical results, including complete tumour clearance in some mesothelioma patients.
Manufacturing of BZDS1901 is being moved to Australia to enhance reliability and scalability.
The placement includes attaching options and requires shareholder approval for part of the issuance.
62 Capital Pty Ltd acted as Lead Manager for the placement.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.